News & Updates

$Sacubitril/valsartan useful in heart failure with reduced ejection fraction$

Sacubitril/valsartan useful in heart failure with reduced ejection fraction

09 May 2022

Treatment with sacubitril/valsartan appears to improve right ventricular performance and pulmonary hypertension among patients with heart failure with reduced ejection fraction (HFrEF), independent of the reverse remodelling of the left ventricle, as reported in a study.

Sacubitril/valsartan useful in heart failure with reduced ejection fraction

09 May 2022

11 causal risk factors for CVD that can be modified

08 May 2022

A systematic Mendelian randomization study has identified several modifiable cardiovascular disease (CVD) causal risk factors, including hypertension, smoking, and high body mass index.

11 causal risk factors for CVD that can be modified

08 May 2022

Platelet function a potential biomarker of Alzheimer’s disease

07 May 2022

A higher platelet response in middle-aged individuals who are free of antiplatelet therapy carries an increased risk of dementia in late life, according to a cohort study with 20 years of follow up.

Platelet function a potential biomarker of Alzheimer’s disease

07 May 2022

Cardiorespiratory fitness offsets aggravating effect of inflammation on sudden cardiac death

06 May 2022

Cardiorespiratory fitness (CRF) and inflammation are both independently linked to sudden cardiac death (SCD) in middle-aged men, reports a recent study. However, better CRF seems to offset the impact of inflammation on SCD risk.

Cardiorespiratory fitness offsets aggravating effect of inflammation on sudden cardiac death

06 May 2022

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

05 May 2022

New drug applications approved by US FDA as of 16-30 April 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

05 May 2022

Women with nonvalvular AF less likely to receive oral anticoagulation, at higher risk of stroke

04 May 2022

Female patients nonvalvular atrial fibrillation (AF) are less often prescribed guideline-recommended oral anticoagulation at the emergency department (ED), which in turn contributes to an increased stroke risk at 1 year regardless of discharge status, a study has found.

Women with nonvalvular AF less likely to receive oral anticoagulation, at higher risk of stroke

04 May 2022

New HF guideline: Quad therapy, HFmrEF, and more

04 May 2022 by

Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.

New HF guideline: Quad therapy, HFmrEF, and more

04 May 2022

Which DOAC is safest to use in AF patients on dronedarone therapy?

02 May 2022 by

Among patients on concomitant treatment with direct oral anticoagulants (DOACs) and dronedarone, no difference is seen in survival free from the composite endpoint (ie, clinically relevant bleeding, thromboembolic event, and all-cause death) and from clinically relevant bleeding between groups of coadministration, according to a study.

Which DOAC is safest to use in AF patients on dronedarone therapy?

02 May 2022

Sticking to a Mediterranean diet protects against pre-eclampsia

01 May 2022

Pregnant women with higher adherence to a Mediterranean‐style diet are at lower risk of pre-eclampsia, with the benefit observed among Black and White women, a study has found.

Sticking to a Mediterranean diet protects against pre-eclampsia

01 May 2022

Elevated lipoprotein(a) ups risk of atrial fibrillation

01 May 2022

Lipoprotein(a) (Lp[a]) appears to play a role in the development of atrial fibrillation (AF), with its effects extending across myocardial tissues, reveals a study.

Elevated lipoprotein(a) ups risk of atrial fibrillation

01 May 2022

News & Updates

Filter by Specialty:

Specialty:

Sacubitril/valsartan useful in heart failure with reduced ejection fraction

Sacubitril/valsartan useful in heart failure with reduced ejection fraction

11 causal risk factors for CVD that can be modified

11 causal risk factors for CVD that can be modified

Platelet function a potential biomarker of Alzheimer’s disease

Platelet function a potential biomarker of Alzheimer’s disease

Cardiorespiratory fitness offsets aggravating effect of inflammation on sudden cardiac death

Cardiorespiratory fitness offsets aggravating effect of inflammation on sudden cardiac death

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

Women with nonvalvular AF less likely to receive oral anticoagulation, at higher risk of stroke

Women with nonvalvular AF less likely to receive oral anticoagulation, at higher risk of stroke

New HF guideline: Quad therapy, HFmrEF, and more

New HF guideline: Quad therapy, HFmrEF, and more

Which DOAC is safest to use in AF patients on dronedarone therapy?

Which DOAC is safest to use in AF patients on dronedarone therapy?

Sticking to a Mediterranean diet protects against pre-eclampsia

Sticking to a Mediterranean diet protects against pre-eclampsia

Elevated lipoprotein(a) ups risk of atrial fibrillation

Elevated lipoprotein(a) ups risk of atrial fibrillation